Theravance Biopharma (TBPH) Posts Quarterly Earnings Results, Misses Expectations By $1.27 EPS
Theravance Biopharma (NASDAQ:TBPH) announced its earnings results on Thursday. The company reported ($1.83) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.56) by $1.27, American Banking News reports.
A number of analysts have recently weighed in on TBPH shares. Analysts at Bank of America initiated coverage on shares of Theravance Biopharma in a research note on Friday, June 6th. They set a “buy” rating and a $34.00 price target on the stock. Analysts at Robert W. Baird initiated coverage on shares of Theravance Biopharma in a research note on Monday, June 2nd. They set a “neutral” rating and a $21.00 price target on the stock.
Shares of Theravance Biopharma (NASDAQ:TBPH) opened at 29.65 on Thursday. Theravance Biopharma has a 1-year low of $14.75 and a 1-year high of $35.675. The stock has a 50-day moving average of $31.29 and a 200-day moving average of $29.0. The company’s market cap is $956.5 million.
Theravance Biopharma, Inc, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (NASDAQ:TBPH)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction.
Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.